Table 2 Correlation between FGFR expression and clinicopathological characteristics of cervical cancer

Normal vs. cancer

 Normal

35 [27–42]

32 [23–40]

106 [89–124]

68 [57–80]

 Cancer

84 [77–91]

70 [64–77]

82 [76–87]

129 [122–136]

 P value

<0.001

<0.001

0.02

<0.001

Stage

 IB1/IIA

82 [75–90]

72 [64–79]

83 [76–89]

130 [121–138]

 IB2/IIB

89 [70–107]

66 [48–83]

79 [65–93]

117 [97–136]

 P value

0.520

0.520

0.630

0.220

Cell type

 SCC

78 [71–86]

77 [69–85]

89 [82–96]

133 [124–141]

 AD/ASC

99 [83–115]

51 [40–62]

59 [48–71]

113 [98–128]

 P value

0.020

<0.001

<0.001

0.020

Tumor size

 ≤4 cm

85 [77–93]

74 [667–83]

83 [76–90]

131 [122–139]

 >4 cm

79 [64–91]

59 [47–70]

79 [68–89]

120 [105–134]

 P value

0.330

0.020

0.500

0.210

LVSI

 Negative

84 [75–93]

73 [64–82]

84 [76–93]

137 [127–147]

 Positive

82 [71–93]

67 [57–77]

78 [70–87]

114 [104–126]

 P value

0.770

0.390

0.330

0.004

Depth of invasion

 <50 %

88 [75–101]

73 [60–86]

85 [74–97]

132 [118–146]

 >50 %

81 [73–90]

70 [62–78]

80 [73–87]

126 [117–135]

 P value

0.420

0.670

0.490

0.470

LN metastasis

 Negative

83 [75–91]

74 [66–82]

84 [77–91]

132 [124–141]

 Positive

84 [70–98]

60 [48–72]

75 [65–83]

114 [98–129]

 P value

0.920

0.048

0.160

0.040

PM involvement

 Negative

85 [78–93]

73 [66–80]

83 [77–90]

129 [121–137]

 Positive

65 [48–82]

49 [34–64]

64 [50–78]

115 [91–139]

 P value

0.030

0.005

0.010

0.250

Resection margin

 Negative

83 [76–90]

71 [64–78]

82 [76–88]

128 [121–136]

 Positive

88 [50–127]

70 [42–99]

80 [52–108]

118 [75–161]

 P value

0.780

0.970

0.890

0.620

Primary treatment

 OP only

84 [74–94]

81 [70–91]

91 [81–100]

136 [125–147]

 OP + RT

81 [66–96]

67 [53–81]

73 [62–85]

127 [111–143]

 OP + CCRT

83 [70–96]

54 [45–64]

71 [62–81]

115 [100–129]

 Neoadjuvant

86 [2–171]

96 [17–175]

96 [20–173]

119 [38–199]

 P value

0.990

0.051

0.120

0.180